Romidepsin - Celgene Corporation
Alternative Names: Depsipeptide; FK 228; FR 901228; Istodax; NSC 630176; NSC 630176D; RMDLatest Information Update: 15 Dec 2023
At a glance
- Originator Astellas Pharma
- Developer Canadian Cancer Trials Group; Celgene Corporation; Columbia University; Lymphoma Academic Research Organisation; University of Birmingham; University of California at San Francisco; University of Kansas Medical Center; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Cytostatic antibiotics; Depsipeptides; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cutaneous T-cell lymphoma
- Registered Peripheral T-cell lymphoma
- Phase I/II Lymphoid leukaemia; Multiple myeloma; T-cell leukaemia; T-cell lymphoma; Triple negative breast cancer
- No development reported Diffuse large B cell lymphoma; Haematological malignancies
- Discontinued Pancreatic cancer; Prostate cancer; Renal cell carcinoma
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 01 Nov 2023 Celgene completes a phase I/II trial in Multiple myeloma (Combination therapy, Second-line or greater) in the USA (IV) (NCT01755975)
- 13 Dec 2022 The Lymphoma Academic Research Organisation completes a phase III trial for Peripheral T-cell lymphoma (First line therapy, Combination therapy)in Belgium, France, Germany, Italy, South Korea, Portugal, Singapore and Spain (IV, Infusion) (NCT01796002)